US FDA Considering Opioid Mail-Back Envelope Mandate, But Industry Has Heard This Before

 
• By Derrick Gingery

Sponsors would be required to furnish patients with pre-paid envelopes to mail back unused opioid medications for disposal. Comments on FDA's proposal could follow industry concerns about burden on health care system voiced when the idea was floated in 2018.

drug mailed in envelope
The FDA described two potential options for mandating pre-paid mail-back envelopes under the opioid REMS in a Federal Register notice. • Source: Shutterstock

More from Drug Safety

More from Pink Sheet